In obesity, BARD (BMI, AST/ALT Ratio, presence of Diabetes) score, positive for values ≥2, is a non-invasive marker of liver fibrosis. Unbalanced dietary habits are related to metabolic and liver dysfunctions. The aims were to investigate in Italian obese patients the prevalence of insulin resistance (IR) and positive BARD; the evaluation of excessive, or deficient, nutrient intakes and their relationship with IR and/or liver fibrosis. From the 220 records, 198 obese patients were included. Anthropometric measurements, HOMA-IR, BARD score and the nutrient intakes, as variances over or below the Recommended Dietary Allowances (RDAs) by the dietary assessment, were calculated as 50th (25th, 75th) percentile. HOMA-IR was in 68% averaging 3.53 ...
Fatty liver at ultrasounds, with/without raised plasma levels of hepatic enzymes, is common in obesi...
Insulin resistance is the pathophysiological precursor of type 2 diabetes mellitus (DM-2), and its r...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...
Objective. We investigated the prevalence of insulin resistance, elevated liver enzymes, and NAFLD F...
Background and aim: In obesity NAFLD is associated with insulin resistance (IR), that may induce adv...
Background and aim: Non-normal serum alanine aminotransferase (ALT) levels and elevation of homeosta...
Background and aim: Few reports have focused on the dietary habit in Italian obese patients and the ...
Background and aim: In obesity with no history of alcohol abuse, liver steatosis (NAFLD) is associat...
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, diabetes and insulin resistanc...
Objective: We correlated dietary profile and markers of visceral and somatic obesities in nonalcohol...
Background and aim: In obesity, nonalcoholic fatty liver disease (NAFLD) is mostly associated with ...
Background and aim: In obesity, a cluster of metabolic alterations is often associated with Fatty Li...
BACKGROUND/AIMS: In the absence of other causes, obesity increases the risk of liver disease. We eva...
none10ABSTRACT Fatty liver at ultrasounds, with/without raised plasma levels of hepatic enzymes, is...
Rates of non-alcoholic fatty liver disease (NAFLD) vary dramatically among Hispanic subpopulations, ...
Fatty liver at ultrasounds, with/without raised plasma levels of hepatic enzymes, is common in obesi...
Insulin resistance is the pathophysiological precursor of type 2 diabetes mellitus (DM-2), and its r...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...
Objective. We investigated the prevalence of insulin resistance, elevated liver enzymes, and NAFLD F...
Background and aim: In obesity NAFLD is associated with insulin resistance (IR), that may induce adv...
Background and aim: Non-normal serum alanine aminotransferase (ALT) levels and elevation of homeosta...
Background and aim: Few reports have focused on the dietary habit in Italian obese patients and the ...
Background and aim: In obesity with no history of alcohol abuse, liver steatosis (NAFLD) is associat...
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, diabetes and insulin resistanc...
Objective: We correlated dietary profile and markers of visceral and somatic obesities in nonalcohol...
Background and aim: In obesity, nonalcoholic fatty liver disease (NAFLD) is mostly associated with ...
Background and aim: In obesity, a cluster of metabolic alterations is often associated with Fatty Li...
BACKGROUND/AIMS: In the absence of other causes, obesity increases the risk of liver disease. We eva...
none10ABSTRACT Fatty liver at ultrasounds, with/without raised plasma levels of hepatic enzymes, is...
Rates of non-alcoholic fatty liver disease (NAFLD) vary dramatically among Hispanic subpopulations, ...
Fatty liver at ultrasounds, with/without raised plasma levels of hepatic enzymes, is common in obesi...
Insulin resistance is the pathophysiological precursor of type 2 diabetes mellitus (DM-2), and its r...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...